Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane
Neoadjuvant Endocrinotherapy of Mamma Carcinoma With Exemestane
Sponsor: Austrian Breast & Colorectal Cancer Study Group
This PHASE2 trial investigates Breast Cancer and is currently completed. Austrian Breast & Colorectal Cancer Study Group leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Sep 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Austrian Breast & Colorectal Cancer Study Group
- Pharmacia Austria GmbH
For direct contact, visit the study record on ClinicalTrials.gov .